(Stockholm April 21, 2020) Asarina Pharma AB (publ) today released topline results from its Phase IIb study with Sepranolone for the treatment of PMDD (premenstrual dysphoric disorder). The study demonstrates a positive safety and tolerability profile for Sepranolone. However, while a substantial reduction in PMDD symptoms was achieved across the patient population, a statistically significant…
Full PDF(Stockholm April 14, 2020) Asarina Pharma AB today announces that its Annual Report for 2019 is now available on the company’s website.
Full PDFThe shareholders of Asarina Pharma AB (publ) (the “Company”) are hereby summoned to attend the Annual General Meeting (“AGM”) on 5 May 2020, at 10.00 CEST at Erik Penser Bank, Apelbergsgatan 27 in Stockholm, Sweden. Registration starts at 09.30 CEST and will stop when the meeting starts. NOTE: This is an unofficial translation of the…
Full PDFAsarina Pharma expects to release top-line results of its Phase IIb PMDD study on schedule at the end of April. Asarina Pharma’s other studies on menstrual migraine and Tourette syndrome also remain on track. The company’s digital R&D Day, on March 26, will detail four key metrics it will use to evaluate the efficacy of…
Full PDFAsarina Pharma’s March 26 R&D day will now be streamed live via digital link due to Coronavirus restrictions. The event focuses on preparing for the upcoming study results in the company's leading indication PMDD, and will still include presentations from PMDD practitioners, patients and leading researchers. Asarina Pharma will also host a study results presentation…
Full PDF